[go: up one dir, main page]

NO20070651L - Sammensetninger av statiner med bronkodilatorer - Google Patents

Sammensetninger av statiner med bronkodilatorer

Info

Publication number
NO20070651L
NO20070651L NO20070651A NO20070651A NO20070651L NO 20070651 L NO20070651 L NO 20070651L NO 20070651 A NO20070651 A NO 20070651A NO 20070651 A NO20070651 A NO 20070651A NO 20070651 L NO20070651 L NO 20070651L
Authority
NO
Norway
Prior art keywords
bronchodilators
statins
compositions
glucocorticosteroids
hmg
Prior art date
Application number
NO20070651A
Other languages
English (en)
Inventor
Bertil Lindmark
Anders Ingemar Thoren
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20070651L publication Critical patent/NO20070651L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen tilveiebringer medikamenter som omfatter kombinasjoner av bronkodilatorer, glukokortikosteroider og HMG-CoA-reduktaseinhibitorer (statiner) ved behandling av luftveissykdommer slik som kronisk obstmktiv lungesykdom (COPD).
NO20070651A 2004-07-15 2007-02-05 Sammensetninger av statiner med bronkodilatorer NO20070651L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0415789.7A GB0415789D0 (en) 2004-07-15 2004-07-15 Novel combination
PCT/GB2005/002413 WO2006008437A1 (en) 2004-07-15 2005-06-20 Combinations of stattins with bronchodilators

Publications (1)

Publication Number Publication Date
NO20070651L true NO20070651L (no) 2007-02-05

Family

ID=32893577

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070651A NO20070651L (no) 2004-07-15 2007-02-05 Sammensetninger av statiner med bronkodilatorer

Country Status (14)

Country Link
US (1) US20080004247A1 (no)
EP (1) EP1773319A1 (no)
JP (1) JP2008506674A (no)
CN (1) CN1984653A (no)
AU (1) AU2005263883A1 (no)
BR (1) BRPI0513283A (no)
CA (1) CA2573393A1 (no)
GB (1) GB0415789D0 (no)
IL (1) IL180423A0 (no)
MX (1) MX2007000424A (no)
NO (1) NO20070651L (no)
RU (1) RU2007101518A (no)
WO (1) WO2006008437A1 (no)
ZA (1) ZA200700071B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007149245A (ru) 2005-06-02 2009-07-20 Те Риджентс Оф Те Юниверсити Оф Колорадо (Us) Способ снижения риска развития рака и предраковой дисплазии
JP5336847B2 (ja) * 2006-06-29 2013-11-06 第一三共株式会社 スタチンによる慢性閉塞性肺疾患治療
JP5349302B2 (ja) * 2006-07-05 2013-11-20 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性肺疾患の治療のためのＨＭＧ−ＣｏＡレダクターゼインヒビターとホスホジエステラーゼ４インヒビターとの組合せ物
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
WO2008088617A1 (en) * 2006-12-04 2008-07-24 Regents Of The University Of Colorado Treatment of copd
US20150174157A1 (en) * 2007-06-15 2015-06-25 Kaohsiung Medical University INHALED NO DONOR PIPERAZINYL DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION BY REDUCING VEGF AND RESTORING eNOS IN HYPOXIC PULMONARY ARTERY
ES2604705T3 (es) 2010-03-31 2017-03-08 Ono Pharmaceutical Co., Ltd. Agente preventivo y/o remedio para el síndrome mano-pie
JP4983989B2 (ja) * 2010-03-31 2012-07-25 小野薬品工業株式会社 手足症候群の予防および治療剤
BR112013001119A2 (pt) * 2010-07-16 2016-05-24 Cipla Ltd composição farmacêutica, processo para fabricar uma composição farmacêutica, uso de r(+)budesonida e um broncodilatador, e método de profilaxia ou tratamento de uma doença respiratória, inflamatória ou obstrutiva das vias aéreas
WO2013137009A1 (ja) * 2012-03-14 2013-09-19 株式会社Ｌｔｔバイオファーマ 慢性閉塞性肺疾患改善剤
CA2907566C (en) * 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
WO2014182928A2 (en) 2013-05-08 2014-11-13 Board Of Regents, The University Of Texas System Stat6 inhibitors
BR112016022405A2 (pt) * 2014-03-28 2017-08-15 Univ Liege Composições de ciclodextrina e derivado de budesonida e métodos
US11069054B2 (en) 2015-12-30 2021-07-20 Visiongate, Inc. System and method for automated detection and monitoring of dysplasia and administration of immunotherapy and chemotherapy
CA3090881A1 (en) 2018-03-01 2019-09-06 Comfort Concepts, LLC Seating pad with woven cover
US20210290580A1 (en) * 2018-07-31 2021-09-23 Wen Tan New use of carbamate ß phenylethanolamine analogues for enhancing intracellular clearance of LDL cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects
CN109498625B (zh) * 2018-12-29 2021-04-16 温州医科大学附属第一医院 一种治疗慢性阻塞性肺疾病的药物组合物及其制备方法
CN115337311B (zh) * 2022-09-26 2023-05-09 南京恒道医药科技股份有限公司 一种治疗呼吸系统疾病的组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US20010006656A1 (en) * 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
CA2399396A1 (en) * 2000-02-10 2001-08-16 Yasuo Sugiyama Tnf- .alpha. inhibitors
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases

Also Published As

Publication number Publication date
CA2573393A1 (en) 2006-01-26
GB0415789D0 (en) 2004-08-18
EP1773319A1 (en) 2007-04-18
WO2006008437A1 (en) 2006-01-26
RU2007101518A (ru) 2008-08-20
CN1984653A (zh) 2007-06-20
BRPI0513283A (pt) 2008-05-06
JP2008506674A (ja) 2008-03-06
AU2005263883A1 (en) 2006-01-26
US20080004247A1 (en) 2008-01-03
MX2007000424A (es) 2007-03-07
ZA200700071B (en) 2008-04-30
IL180423A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
NO20070651L (no) Sammensetninger av statiner med bronkodilatorer
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
DK1718336T3 (da) Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
UY28958A1 (es) Nuevos derivados de piridazin-3(2h)-ona
NO20076206L (no) Kombinasjon av PDE4 inhibitor romflumilast og et tetrahydrobioterin-derivativ
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
CR7043A (es) Derivados de eteres utiles como ganetes inhibidores de las isozimas pde4
IL167900A (en) Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease
WO2005084301A3 (en) Compositions and methods for treating diseases
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
WO2007008529A3 (en) Celullar cholesterol absorption modifiers
WO2008116139A3 (en) N-heterocyclic compounds useful as inhibitors of janus kinases
EA201190108A1 (ru) Фармацевтическая композиция для ингаляции
WO2007015866A3 (en) Inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2007071313A3 (en) Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
EA200700037A1 (ru) Производные n-гидроксиамида и их применение
EA200900073A1 (ru) КОМБИНАЦИЯ ИНГИБИТОРОВ HMG-CoA-РЕДУКТАЗЫ И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 4, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
WO2005041864A3 (en) Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
AR047386A1 (es) Uso de pteridinas sustituidas para el tratamiento de enfermedades de las vias respiratorias
WO2007015877A3 (en) Inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2005086915A3 (en) Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
NO20076191L (no) Magnesiumsalter av HMG-COA reduktaseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application